In the Asian region Vitrolife faces a challenging period.
Redeye provides a comment on Scandinavian ChemoTech's recently announced collaboration with a global...
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 21 mars 2025 att Koncernens nyligen...
Acquiring consulting company BlakYaks at 10.7x EV/EBITA Seems to be a good growing and highly profit...
Redeye comments on Paxman’s directed issue to institutional investors, raising SEK123.
Redeye provides its initial take on Xbrane following the sale of its Cimzia biosimilar (XB003) and p...
Redeye comments on the clinical data from the SESAR study and the confusion it brought.
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 19 mars 2025 att Bolaget har erhållit ytter...
Redeye leaves a comment following Magle’s announcement of a randomized controlled multicenter trial ...
Q-linea’s recent progress in extending the commercial network, establishing a pipeline of ASTar eval...
Redsense avslutar 2024 starkt med sitt första helår av vinst.
VBG Group visar fortsatt god lönsamhet trots en utmanande marknad.
Redeye comments on Dignitana’s takeover offer from Paxman, valued at SEK153m (SEK1.
Det fjärde kvartalet kom in under våra förväntningar både vad gäller omsättning och marginaler.
Intäkterna för den fjärde kvartalet uppgick till 0,6 (0,9) miljoner kronor.